Palatin Technologies

company

About

Palatin Technologies is a biopharmaceutical company developing targeted receptor specific peptide therapeutics to treat diseases.

  • 11 - 50

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
$10M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Jan 1, 1986
Number Of Employee
11 - 50
Operating Status
Active

Palatin Technologies is a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for treating diseases with significant unmet medical needs and commercial potential. Their programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Their primary product in clinical development is bremelanotide for treating female sexual dysfunction (FSD). In addition, they have drug candidates or development programs for obesity, erectile dysfunction, pulmonary diseases, cardiovascular diseases, and inflammatory diseases.
Their current focus is on the design and development of receptor-selective melanocortin agonists for inflammation and autoimmune conditions, with a focus on ocular diseases. Their therapeutics work by activating endogenous melanocortin pathways to resolve damaging inflammation and allow affected tissues time to heal. Research has shown melanocortin agonists can prevent and reverse inflammation in disease models, including in the eyes and intestine—two of their targeted areas.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$32.70M
Palatin Technologies has raised a total of $32.70M in funding over 2 rounds. Their latest funding was raised on Dec 24, 2014 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Dec 24, 2014 Post-IPO Debt $10M 1 Detail
Jan 30, 2004 Post-IPO Equity $22.70M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Palatin Technologies is funded by 2 investors. Horizon Technology Finance and Alexandra Investment Management are the most recent investors.
Investor Name Lead Investor Funding Round
Horizon Technology Finance Post-IPO Debt
Alexandra Investment Management Post-IPO Equity